Trump's Comments on Ozempic Price Drop Impact Novo Nordisk and Eli Lilly Stocks

Impact of Trump's Drug Price Comments

• 📉 Novo Nordisk and Eli Lilly shares experienced a decline following President Trump's remarks about significantly lowering the price of Ozempic.
• 💡 Trump stated that the cost of Ozempic, a drug often associated with weight loss, could be reduced to approximately $150 per month.
• 🎯 The current US list price for Ozempic is around $1,000 monthly, making Trump's proposed reduction a substantial potential hit to these companies.

Critical Role of Weight Loss Drugs

• 🚀 For Novo Nordisk, diabetes and weight loss drugs like Ozempic are central to their business, representing their primary revenue streams.
• 🧠 Eli Lilly, while more diversified, relies heavily on its major products such as Mounjaro and Zepbound (similar treatments to Ozempic).
• 📈 These drugs are considered critical to the future growth and expectations of both pharmaceutical giants.

Market Reaction and Drug Pricing

• ⚠️ The market's delayed reaction to Trump's comments may be attributed to the fact that his remarks were made during a press conference initially focused on IVF and fertility drugs.
• 💰 The cash pay market for these drugs is significant, with Lilly reporting that about 20% of Zepbound prescriptions are cash-paid, a share that is growing.
• 💸 A price reduction to $150 would be lower than the current cash pay price, potentially impacting sales and profitability.

Global Drug Price Discrepancies

• 🌍 The $1,000 price tag for Ozempic in the US has been a point of concern for both Republicans and Democrats, highlighting the difference between US drug prices and those in other countries.
• 🤝 Trump's initiatives, such as the "most favored nation" policy, aim to align US drug prices with global benchmarks where governments are more involved in price setting.
• 📉 In countries with government price controls, drug makers typically charge less due to negotiated pricing. In the US, this has historically been less common.

Novo Nordisk's Unique Challenges

• ⚖️ Novo Nordisk faces additional pressure as its drugs, including Ozempic and Wegovy, were selected for price negotiations under the Inflation Reduction Act (IRA).
• 📊 These IRA negotiations, separate from Trump's comments, are already set to reduce the prices of these drugs in Medicare.
• ❓ There is concern that significant price reductions could impact future research and development (R&D) in this lucrative field, though some CEOs have since moderated initial concerns.